Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT01101048
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT01101061
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Phase 3
Completed
- Conditions
- Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 792
- Registration Number
- NCT01080391
- Locations
- 🇺🇸
Providence St. Joseph Medical Center, Burbank, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4509
- Registration Number
- NCT01077154
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Phase 3
Completed
- Conditions
- Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
- Interventions
- Biological: Romiplostim
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 66
- Registration Number
- NCT01071954
- Locations
- 🇪🇸
Research Site, Barcelona, Cataluña, Spain
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT01059435
Safety and Efficacy of AMG 827 in Subjects With RA
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 211
- Registration Number
- NCT01059448
- Locations
- 🇬🇧
Research Site, Merseyside, United Kingdom
Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: CCX 354-C
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT01027728
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 159
- Registration Number
- NCT01028963
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 397
- Registration Number
- NCT01018550
© Copyright 2025. All Rights Reserved by MedPath